Production (Stage)
Barinthus Biotherapeutics plc
BRNS
$0.654
-$0.156-19.26%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -100.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -100.00% | |||
| Cost of Revenue | 11,428.99% | -82.49% | |||
| Gross Profit | -11,428.99% | -100.47% | |||
| SG&A Expenses | 484.87% | -124.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 84.24% | 12.38% | |||
| Total Operating Expenses | 672.33% | -88.94% | |||
| Operating Income | -672.33% | 70.85% | |||
| Income Before Tax | 4.41% | -153.17% | |||
| Income Tax Expenses | -833.33% | 200.00% | |||
| Earnings from Continuing Operations | 4.53% | -153.30% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -80.39% | 240.00% | |||
| Net Income | 4.34% | -153.14% | |||
| EBIT | -672.33% | 70.85% | |||
| EBITDA | -849.68% | 75.94% | |||
| EPS Basic | 4.59% | -148.54% | |||
| Normalized Basic EPS | -964.95% | 78.36% | |||
| EPS Diluted | 4.20% | -143.57% | |||
| Normalized Diluted EPS | -964.95% | 78.36% | |||
| Average Basic Shares Outstanding | 0.27% | 1.87% | |||
| Average Diluted Shares Outstanding | 0.27% | 1.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||